NY-AQARA
Aqara, a leading provider of smart home products, announced the launch of its new Motion Sensor P1, an updated model of the best-selling Aqara Motion Sensor. The sensor is a PIR motion and motion-light sensor that detects motion as well as the ambient light status in the room, and can be used for home security and automation. Built on the previous generation, the P1 model further extends the battery life to a record length of up to 5 years*, thanks to more power-efficient technologies and the improved batteries. The new sensor has been made available on Amazon in the US , Canada , Germany and France , as well as via selective Aqara retailers in North America, Europe, Asia and Oceania**. It is expected to hit Amazon UK in the following weeks.
Based on the Zigbee 3.0 protocol which allows faster response, higher reliability and better compatibility, the Motion Sensor P1 adds more flexibility for users including a configurable detection timeout and the adjustable sensitivity level. No longer fixed at a 60-second timeout like the predecessor, the P1 sensor allows users to set the detection timeout between 1 to 200 seconds on the Aqara Home app. It’s also possible to set the sensitivity level to high, medium or low, which refers to the distance from which the sensor will be triggered from, so that false alarms could be reduced. By default which is medium sensitivity, the sensor supports a field of view (FoV) of 170° for up to 2 meters and 150° for up to 7 meters.
The P1 motion sensor are compatible with major smart home ecosystems including HomeKit, Alexa, IFTTT and more. Moreover, the sensor will support Matter - the new connectivity standard for IoT devices - via an OTA update of Aqara hubs after the Matter rollout. The sensor itself also supports OTA updates, which means that new features and fixes now can be added after the release of the product.
Motion sensor has become increasingly popular among smart home users, as it is a natural part of the majority of smart home automations. The combination of an Aqara hub, a Motion Sensor P1 and controller devices like smart wall switches and roller shade drivers can automate many routine tasks, such as turning on the lights, opening the sun shades or controlling the TV. Moreover, with P1’s built-in light sensor, the lights could be controlled more precisely. For example, users could set to turn on the hallway lights only when it’s dark and motion is detected, so that energy consumption is reduced, and the lifespan of lights is increased.
To celebrate the launch, Aqara now offers a 10% discount for the new Motion Sensor P1 on its Amazon brand stores. North American customers will enjoy the offer with the promo code MOTIONUS in the US and Canada , while European customers will enjoy it using the promo code EUMOTIONPI in Germany and France . Both codes will be valid through April 29, 2022.
For more details of the Motion Sensor P1, please visit our website .
* Based on lab test, on the assumption of LED trigger indicator disabled and detection timeout of no less than 30 seconds.
** Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
